NCT04899336

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

CompletedPHASE3INTERVENTIONAL

Trial Details

Start: 2021-06-30Est. Completion: 2025-08-27

Enrollment target: 17,797 participants

Locations

Lakeview Clinical Research, Guntersville, Alabama, United States
Hope Research Institute, Phoenix, Arizona, United States
Hope Research Institute, Phoenix, Arizona, United States
Interspond-Clinical Research Institute of AZ, Sun City West, Arizona, United States
Baptist Health Center For Clinical Research, Little Rock, Arkansas, United States
Sun Urology - Buena Park Office, Buena Park, California, United States
Hope clinical Research LLC, Canoga Park, California, United States
Velocity Clinical Research, Inc., Chula Vista, California, United States
Marvel Clinical Research, Huntington Beach, California, United States
California Adult Circumcision - Alvarado La Mesa Urology Center, La Mesa, California, United States
Om Research LLC, Lancaster, California, United States
Atlantic Urology Medical Group, Long Beach, California, United States
Long Beach Clinical Trials, LLC, Long Beach, California, United States
American Institute of Research, Los Angeles, California, United States
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with…

Huntsville, United StatesCompleted Feb 19, 2024

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.